All In Biotech

NDA 021990 · Novartis

Exforge

Amlodipine Besylate, Valsartan · Oral · Angiotensin 2 Receptor Blocker

Last checked: Nov 19, 2026Latest source record: Apr 7, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Jun 20, 2007

Approved uses

2

Original approval plus efficacy supplements

Registered trials

656

178 Phase 3, 22 recruiting

FAERS reports

11,054

9,506 serious, 1,273 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue Exforge as soon as possible. (5.1) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. (5.1) WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue Exforge as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 )

What it is approved for

From the label in effect Feb 17, 2026.

Exforge is the combination tablet of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB), and valsartan, an angiotensin II receptor blocker (ARB). Exforge is indicated for the treatment of hypertension, to lower blood pressure: In patients not adequately controlled on monotherapy ( 1 ) As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals ( 1 ) Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Figure 1: Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 Figure 2: Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 Figure 3: Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 Figure 4: Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 1.1 Hypertension Exforge (amlodipine and valsartan) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine and the angiotensin II receptor blocker (ARB) class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with Exforge. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published...

Mechanism: Amlodipine Amlodipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • EXFORGE · AMLODIPINE BESYLATE EQ 10MG BASE; VALSARTAN 320MG · TABLET, ORAL · Prescription · TE AB
  • EXFORGE · AMLODIPINE BESYLATE EQ 10MG BASE; VALSARTAN 160MG · TABLET, ORAL · Prescription · TE AB
  • EXFORGE · AMLODIPINE BESYLATE EQ 5MG BASE; VALSARTAN 320MG · TABLET, ORAL · Prescription · TE AB
  • EXFORGE · AMLODIPINE BESYLATE EQ 5MG BASE; VALSARTAN 160MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Amlodipine" as an intervention, any sponsor and status, largest first.

All 656 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood pressure increased662
  • hypertension589
  • drug ineffective553
  • dizziness495
  • malaise471
  • death470
  • fatigue445
  • fall430
  • headache401
  • dyspnoea364
  • oedema peripheral354
  • diabetes mellitus353

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200758
2008276
2009478
2010542
2011873
20121,107
2013885
2014812
2015776
2016683
2017593
2018759
2019612
2020599
2021548
2022469
2023347
2024238
2025214
2026185

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Exforge (Amlodipine Besylate/Valsartan)

2024 spending

$2.1M

Beneficiaries

575

2,644 claims

Per beneficiary

$3,572

$11.97 per unit

View as table
YearSpending
2020$4,194,448
2021$3,366,507
2022$2,451,432
2023$2,393,677
2024$2,053,871

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,807 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.